Post-surgical follow-up (by ELISA and immunoblotting) of cured versus non-cured cystic echinococcosis in young patients by Nouir, N Ben et al.
Post-surgical follow-up (by ELISA and immunoblotting)
of cured versus non-cured cystic echinococcosis in
young patients
N. BEN NOUIR1, S. NUN˜EZ2, E. FREI2, M. GORCII1, N. MU¨LLER2, C. GIANINAZZI2,
M. MEKKI3, A. NOURI3, H. BABBA1 and B. GOTTSTEIN2*
1University of Monastir, Faculty of Pharmacy, Department of Clinical Biology B, Laboratory of Parasitology and Mycology,
99UR/08-05 1– rue Avicenne, 5000 Monastir Tunisia
2 Institute of Parasitology, University of Bern, La¨ngass-Strasse 122, CH-3001 Bern, Switzerland
3E. P. S. Fattouma Bourguiba, Pediatric Surgery Service,Monastir 5000, Tunisia
(Received 10 January 2007; revised 15 March and 27 June 2007; accepted 4 July 2007; ﬁrst published online 4 September 2007)
SUMMARY
The study was designed to determine comparatively the prognostic value of immunoblotting and ELISA in the serological
follow-up of young cystic echinococcosis (CE) patients exhibiting either a cured or a progredient (non-cured) course of
disease after treatment. A total of 54 patients (mean age 9 years, range from 3 to 15 years) with surgically, radiologically and/
or histologically proven CE were studied for a period up to 60 months after surgery. Additionally, some of the patients
underwent chemotherapy. Based on the clinical course and outcome, as well as on imaging ﬁndings, patients were clustered
into 2 groups of either cured (CCE), or non-cured (NCCE) CE patients. ELISA showed a high rate of seropositivity 4 to 5
years post-surgery for both CCE (57.1%) and NCCE (100%) patients, the diﬀerence found between the two groups was
statistically not signiﬁcant. Immunoblotting based upon recognition of AgB subcomponents (8 and 16 kDa bands) showed
a decrease of respective antibody reactivities after 4 years post-surgery. Only sera from 14.3% of CCE patients recognized
the subcomponents of AgB after 4 years, while none (0%) of these sera was still reactive at 5 years post-surgery. At variance,
immunoblotting remained positive for AgB subcomponents in 100% of the NCCE cases as tested between 4 and 5 years
after surgical treatment. Immunoblotting therefore proved to be a useful approach for monitoring post-surgical follow-ups
of human CCE and NCCE in young patients when based upon the recognition of AgB subcomponents.
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INTRODUCTION
Hydatidosis or cystic echinococcosis (CE) is a zo-
onosis caused by infection with the larval stage of
the cestode tapeworm Echinococcus granulosus. The
parasite has a cosmopolitan distribution with a high
prevalence documented in some areas such as North
Africa, Australia and South America (Eckert et al.
2000; McManus et al. 2003). In Tunisia, human
CE is a public health concern with an annual surgical
incidence estimated at 15 cases/100000 inhabitants
(Ministe`re de la Sante´ Publique, 1993; Oudni-
M’Rad et al. 2007). Diagnosis of CE is mostly based
on clinical ﬁndings (X-ray, ultrasonography [US],
computed tomography [CT] andmagnetic resonance
imaging [MRI]). In certain cases immunodiagnosis
is a useful support for the clinical diagnosis and to
conﬁrm the hydatid nature of the cyst (Babba et al.
1994). Approximately 10% of the CE cases occur in
children, but in certain areas, e.g. in some countries
of North Africa, the percentage of young patients
may be much higher (Oudni-M’Rad et al. 2007).
Surgery is the treatment of choice, oﬀering in
certain cases a complete cure and recovery. However,
in some cases of complicated cysts (such as ﬁssured or
super-infected), surgical procedures and inadequate
cyst removal can lead to the spillage of parasite
material including protoscoleces, which can be the
origin of newly developing cysts and thus relapse of
disease. Another post-surgical complication is the
appearance of ‘new’ cysts not previously detected
due to their size and/or localization.
One of the major problems of human CE en-
countered by clinicians is the frequency of relapses,
aﬀecting approximately 2–20% of cases after surgery
according to WHO (2001) and 14–25% of cases after
chemotherapy, according to Franchi et al. (1999)
and Pawlowski et al. (2001). Therefore, there is a
need for evaluation of markers which could be
used post-operatively, that allow rapid detection of
newly growing or relapsing cysts. Many serological
tests have been used for post-surgical or post-
treatment follow-up of hydatidosis, including
the indirect haemagglutination (IHA) test, the
enzyme-linked immunosorbent assay (ELISA), and
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immunoblotting (Force et al. 1992; Ravinder et al.
1997; Zarzoza et al. 1999; Gadea et al. 2000; Bulut
et al. 2001;Doiz et al. 2001; Rigano et al. 2002; Lawn
et al. 2004). Their usefulness for monitoring CE
patients after surgery was variable among diﬀerent
laboratories, a fact that may be related to the type and
procedure of antigen preparation used (Lightowlers
and Gottstein, 1995). The period of time between
surgery and serum collection is important with re-
gard to the predictive value indicating either recov-
ery or relapse. Few studies have been designed so far
to evaluate modern immunodiagnostic tests for their
predictive value after surgery, and/or chemotherapy
(Moosa and Abdel-Hafez, 1994; Zarzosa et al. 1999;
Rigano et al. 2002; Nasrieh and Abdel-Hafez, 2004).
One promising approach was recently reported
by Hernandez et al. (2005) who demonstrated a
correlation between selected risk factors for CE and
seropositivity using crude antigens of E. granulosus
(ELISA) or puriﬁed antigen B. An improved
immunodiagnostic performance was achieved using
a synthetic peptide derived from the antigen B
sequence (Gonzales-Sapienza et al. 2000). This
peptide had not been evaluated for the post-operative
follow-up of CE patients.
In the present study, we assessed ELISA and
immunoblotting as tests for post-therapeutical fol-
low-up of CE in young patients. Children and ado-
lescents, when compared to adult CE patients, more
frequently present immunodiagnostic problems
post-operatively (WHO, 2001). Children not only
represent the largest proportion of CE patients
when clustered according to age distribution (WHO,
2001), but young patients also require special atten-
tion with regard to surgical and medical intervention
(Dincer et al. 2006; Durakbasa et al. 2006). Also, in
relatively high endemic areas such as Tunisia, CE
commonly starts during childhood or adolescence
(Oudni-M’Rad et al. 2007). The young CE patients
participating in the present study were placed either
into a cured (CCE) group of patients, which pre-
sented no signs of relapse for a period of up to 4–5
years following initial treatment, or into a non-cured
(NCCE) group who presented still active cysts at 4–5
years following initial treatment or diagnosis, and
despite an initial attempt to curative surgery of the
cysts in all but 2 of these cases.
MATERIALS AND METHODS
Sera from CE patients
A total of 290 sera were collected from 54 children or
adolescents aﬀected by CE (mean age 9 years, range 3
to 15 years). In each case a ﬁrst sample was obtained
at the time of diagnosis (prior to medical inter-
vention, day 0) and further samples during a follow-
up period ranging between 7 days and 5 years
post-surgery and/or chemotherapy (Table 1). The
intervals and numbers of follow up steps were
variable between the patients, and the mean serum
sample number per patient was 7¡2. All specimens
were stored at x20 xC prior to laboratory testing.
For follow-up studies, all patients were subjected to
serological and radiological investigation 1 week after
surgery and/or start of chemotherapy, then 1 month,
6 months and subsequently once per year. Clinical
and parasitological examinations were carried out at
the E.P.S. Hospital of Monastir (Tunisia) in the
Pediatric Surgery Service and in the Laboratory
of Diagnostic Parasitology of Monastir University.
The patients were reviewed with respect to para-
meters like number and anatomical localization of
the cyst(s), radiological determination of the type
of the cyst(s) (according to the guidelines published
by WHO, 2003), clinical complications and need of
benzimidazole treatment.
Forty CCE-patients had cured or stable disease
with no clinical or radiological evidence of recurrence
or remaining cyst activity through a follow-up period
ranging between 1 and 5 years (Table 1). Five
showed totally calciﬁed hepatic cysts at their last
time-point.
Fourteen NCCE-patients were still sick at the
end of the study, despite an initial attempt to carry out
Table 1. Overview of the clinical features of the two groups of CE patients included in the present study
(For CCE patients, chemotherapy (albendazole, ABZ) was added to surgery when cysts were considered as ﬁssured. In
NCCE patients, ABZ was administered in cases exhibiting ﬁssured cysts, multiple cysts, and disseminated or inoperable
cysts left after surgery.)
n
Sex
Age
(mean years)
Cyst localization Therapy
Follow-up
(years)F M Lungs Liver Multiple* n
Period
(months)
Surgery
only
ABZ
only
Surgery
plus ABZ
Cured
(CCE)
40 16 24 9 (3–15) 18 11 11 6 2–48 34 0 6 3¡2 years
Non-cured
(NCCE)
14 4 10 9 (4–14) 5 6 3 9 12–60 5 2 7 3¡2 years
* Multiple locations indicate cysts detected in the liver and the lungs (10 cases), liver and spleen (1 case), liver and
mediastinum (1 case), liver, lungs and heart (2 cases).
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curative surgery of the cysts: 12 of them ﬁnally pre-
sented active cysts and progressive disease (3 patients
suﬀered fromﬁssured lung cysts, 6 had liver cysts and
3hadmultiple localizations, including liver/spleen for
1patientand liver/lungs for2patients) at theendof the
study period. Another 2 patients were initially con-
sidered as inoperable cases and were treated with al-
bendazole only (Zentel 10 mg/ kg/ day) for 5 and 3
years, respectively. In both patients disseminated
cysts were visualized upon radiological examination.
All NCCE patients presented at least 1 intact/viable
cyst at the end of the follow-up study period, as de-
tected by radiological examination.
In summary, 54 patients were clustered into 2
diﬀerent groups i.e. (A) cured or inactive hydatid
disease cases (CCE; n=40/54), where the hydatid
cyst had disappeared following surgery or had fully
calciﬁed in 5 cases, and the other cases remaining
inactive for the study period, and (B) cases with
active CE (NCCE; n=14/54) who presented a
progressive form of disease after an obviously
unsuccessful surgical intervention, or where no
surgery was possible. Sera were collected at various
time-intervals ranging from 1 week to 60 months
post-surgery, and then tested in both ELISA and
immunoblotting.
Antigens
Crude hydatid ﬂuid (CHF) was obtained in Sardinia
by aspiration from fertile sheep liver cysts. Inclusion
criteria for CHF was fertility, a clear ﬂuid consist-
ency and a protein concentration of >0.95 mg per
ml. The CHF was supplemented with 1% 100 mM
PMSF (phenylmethyl sulfonyl ﬂuoride) solution,
and subsequently sedimented at 10 000 g at 4 xC for
30 min. The supernatant was stored atx20 xC until
used for ELISA and immunoblotting.
SDS-PAGE
Parasite antigens were separated on a 5–20% linear
gradient polyacrylamide gel as described by Poretti
et al. (1999), using reducing and non-reducing con-
ditions in parallel for comparative purposes (Bio-Rad
apparatus). CHF, after thawing, was brought
into 10 mM Tris-HCl with 10% SDS and 9 M urea,
and heated either for 20 min at 65 xC (non-
reducing condition) or for 5 min at 100 xC with 5%
b-mercaptoethanol (reducing condition). Proteins
were loaded at a concentration of 150 mg/gel, and the
electrophoresis was done at 500 V for 2 h at 4 xC.
Immunoblotting
Electrophoretically resolved proteins were trans-
ferred onto nitrocellulose membranes as previously
described by Poretti et al. (1999). Nitrocellulose
strips (3 mm wide) were then incubated with human
sera diluted at 1 : 100 in phosphate-buﬀered saline
containing 0.3% Tween and 5% skim milk powder
overnight at 4 xC; strips were then washed and in-
cubated with goat anti-human IgG horseradish
peroxidase conjugate (Sigma A6029; diluted 1 : 200)
for 2 h at room temperature. Immunoreactive anti-
genic bands were visualized using 3,3k-diamino-
benzidine tetrahydrochloride (DAB) and 0.03‰
H2O2. The main diagnostic bands yielded in the
immunoblot carried out under reducing conditions
were the 8, 12, 16, 21 and 37 kDa bands. Under non-
reducing conditions, bands that localized at 8, 12, 16,
21, 55 and 65 kDa were considered as diagnostically
relevant. In order to report a positive serology, at
least 1 of the AgB components had to show up. These
AgB subunits localized at 8 and 16 kDa for both re-
ducing and non-reducing conditions (Lightowlers
and Gottstein, 1995).
Enzyme linked immunosorbent assay (ELISA)
Nunc Immulon ELISA microplate strips were
coated with 100 ml per well of CHF diluted in ELISA
coating buﬀer (0.1 M Na HCO3/Na2CO3, pH 9
.6,
containing 0.02% NaN3) to a concentration of 10 mg/
ml. ELISA strips were washed 3 times with washing
buﬀer (PBS, 3% Tween 20) and blocked with
blocking buﬀer containing 0.05% bovine haemo-
globin and 0.02% sodium azide in PBS, pH 7.2. Sera
were diluted 1 : 100 in blocking buﬀer, and alkaline-
phosphatase-labelled anti-human IgG conjugate
(Sigma A 5403) was used at a 1 : 2500 dilution. All
incubations were done at 37 xC for 30 min. Plates
were ﬁnally washed 3 times and then incubated with
the substrate for 15 min. The reaction was stopped
with 3 M NaOH. The absorbances (A) were mea-
sured at 405 nm using a microplate reader (Dynex
Technologies Bioconcept). The results were ex-
pressed in arbitrary deﬁned antibody units (AU),
which relate antibody activity in the test serum to a
positive reference serum with an arbitrary antibody
activity of 100 AU (Gottstein et al. 1993).
Mathematically, AU were deﬁned by the following
formula:
Absorbance A405 nm of
test serumxcut-off value*
Absorbance A405 nm of positive
reference serumxcut-off value*
r100
The cut-oﬀ value(*) was determined based upon a
threshold determined by the mean of the respective
A405 nm values plus 3 standard deviations (cf.
Gottstein et al. 2001) of 100 blood donor sera, i.e.
the A405 nm-values of negative sera were ranging
within the 99% conﬁdence limit of a healthy control
population. When plotted, the respective A405 nm
values essentially represented a normal distribution.
Inter-test and intra-test variations were assessed by
determining the coeﬃcients of variation for reference
Serological follow-up of cystic echinococcosis 107
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0031182007003502
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 15:07:48, subject to the Cambridge Core terms of use, available at
negative and positive sera, all having been tested in
triplicate on each test plate; variation of f15% was
recorded, which is considered acceptable for im-
munological assays (Pﬁster et al. 1999). Since this
latter ﬁnding was essentially the same as that de-
scribed previously for the EgHF-ELISA (Gottstein
et al. 1993), no modiﬁcation was required for the
present study.
Protein concentration
Protein concentrations were determined using the
Bio-Rad Bradford protein assay and bovine plasma
immunoglobulin as a standard.
Statistical analyses
The Epi Info 6 program was used to calculate the
Chi-square-test for comparing the rates of sero-
positivity between each group of patients during each
period of follow-up. Pf0.05 was considered as
statistically signiﬁcant.
RESULTS
ELISA
The post-treatment evolution of antibody concen-
trations was comparatively assessed in CCE cases
versus NCCE patients. Antibody levels were
arbitrarily clustered into high (85–185 AU), medium
(25–80 AU), low (5–20 AU) and negative (<1AU).
CCE patients whowere cured by radical cyst removal
or who ﬁnally presented ‘stable’ non-viable cysts
showed diﬀerent antibody kinetics than NCCE pa-
tients who presented active (viable) cyst(s) (Table 2)
at the end of the study period. In CCE patients,
antibody levels increased within the ﬁrst 6 months
post-surgery in most cases with 7 (Table 2A) initially
seronegative CE patients becoming seropositive at
1 month post-surgery. Subsequently, in most pa-
tients antibody levels decreased progressively with
time, 12 out of 40 patients (30%) being seronegative
at the end-point of the serodiagnostic investigation,
which varied between 1 and 5 years post-surgery. In
contrast, most NCCE patients maintained high
antibody levels (>85 AU), with a few in the medium
(>25 AU) antibody concentration class. An actual
decrease of antibody levels was not found for the
whole study time-period of up to 5 years in these
patients (Table 2B). With regard to the overall ﬁnal
serodiagnostic positivity of ELISA, 71.4% of the
CCE patients were still seropositive at 4 years post-
surgery and 57.1% at 5 years post-surgery. Further-
more, 2 CCE patients, who had fully calciﬁed
(surgically non-resected) cysts, still showed high
antibody concentrations of 106 and 95 AU at 4 years
post-surgery, and 3patients had antibody levels of 84,
39 and 84 AU after 2, 5 and 1 year post-surgery,
Table 2. Percentage of seropositivity determined by ELISA in 40 patients with CCE (A) and 14 NCCE
patients (B) plotted against the follow-up time
(D0: serum samples collected before surgery and/or initiation of therapy; D7: sample collected 1 week after surgery, 1M:
one month after, 6M: six months after, 12M: twelve months; and so on. *Numbers in parenthesis indicate number of cases
examined (P>0.05).)
(A)
AU
D0
(33)*
D7
(29)*
1M
(31)*
6M
(34)*
12M
(30)*
24M
(26)*
36M
(15)*
48M
(7)*
60M
(7)*
n % n % n % n % n % n % n % n % n %
85–185 13 39.4 18 62 22 71 18 52.9 8 26.6 5 19.2 2 13.3 1 14.3 1 14.3
25–80 5 15.1 5 17.2 3 9.6 8 23.5 13 43.3 12 46.1 4 26.6 1 14.3 0 0
5–20 3 9 1 3.4 1 3.2 2 5.8 3 10 3 11.5 5 33.3 3 42.8 3 42.8
<1(Negative) 12 36.4 5 17.2 5 16.1 6 17.6 6 23.3 6 23 4 26.6 2 28.5 3 42.8
Seropositivity 21 63.6 24 82.7 26 84 28 82.3 24 80 20 77 11 73.3 5 71.4 4 57.1
(B)
D0
(12)*
D7
(7)*
1M
(11)*
6M
(12)*
12M
(13)*
24M
(11)*
36M
(7)*
48M
(3)*
60M
(2)*
AU n % n % n % n % n % n % n % n % n %
85–185 9 75 5 71.4 11 100 12 100 11 84.6 9 81.8 6 85.7 3 100 2 100
25–80 1 8.3 1 14.3 0 0 0 0 2 15.4 2 18.1 1 14.3 0 0 0 0
5–20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
<1 (Negative) 2 16.6 1 14.3 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Seropositivity 10 83.3 6 85.7 11 100 12 100 13 100 11 100 7 100 3 100 2 100
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respectively. The decrease of antibody concen-
trations with time was considerably slower in these
cases when compared to surgically treated CCE
patients.
In NCCE patients, high antibody levels persisted
in all of the patients (Table 2B). Overall, however,
there was no statistically signiﬁcant diﬀerence
(P>0.05) in seropositivity of samples from cured
individuals (CCE) and those from NCCE patients at
any time-point of the follow-up period.
With ELISA, 12 out of 34 (66.6%) CCE patients
treated by surgery alone reached seronegativity by
their last serum sample. None of the 6 patients who
received combined surgery/ABZ-treatment were
negative at the end of the follow-up period.However,
the diﬀerences in antibody concentrations between
CCE patients who underwent combined surgery and
ABZ-therapy versus those treated surgically were
statistically not signiﬁcant. Nevertheless, in both
approaches a progressive decrease of antibody con-
centrations was observed (data not shown).
Immunoblotting
Immunoblotting proﬁles obtained with sera from 30
out of 40 CCE and all NCCE patients showed an
initial (day 0) strong recognition of 4 major bands
localizing at 8, 12, 16, and 21 kDa for both reducing,
and non-reducing conditions (Figs 1–3). Two of
these bands (8 and 16 kDa) were attributed to AgB
subcomponents as referenced by Lightowlers
and Gottstein (1995). Another two bands at 55 and
65 kDa appeared under non-reducing (Fig. 2) con-
ditions, while a 37 kDa band was visualized under
reducing (Fig. 3) conditions. These 55/65 kDa and
37 kDa bands were also recognized by negative
control sera, thus demonstrating a non-speciﬁcity of
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Fig. 1. Temporal evolution of AgB-band-recognition by immunoblotting in 30 CCE (A) and 14 NCCE patients (B)
before and after treatment. Sera from 10 CCE patients with lung cysts, who were persistently seronegative by
immunoblotting between day 0 and 5 years after diagnosis, were not included in this ﬁgure. D0: serum samples
collected before surgery, D7: one week after surgery, 1M: one month after, 6M: six months after, 12: twelve months
after treatment, and so on. * P<0.05 (between A and B).
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these signals. Clearly diﬀerent patterns became evi-
dent between the two groups of patients over time.
Sensitivity based on the detection of at least 1 of the
AgB subcomponents, decreased sharply from 77.4%
to 50%within 1month and 6months, respectively, in
CCE cases, and subsequently to 14.3% at 4 years
after surgical treatment (Fig. 1A). No detectable
bands were observed 5 years post-surgery in these
patients (Fig. 1A). However, in 5 CCE patients
whose clinical examination had indicated the pres-
ence of calciﬁed cysts, and who were estimated as
clinically cured from hydatidosis, at least 1 of the
antigen B subcomponents remained immunoreactive
during a relatively long time of follow-up. In-
terestingly, we noticed the complete absence of anti-
AgB antibody reactivity before surgery and during
follow-up in 10 out of 18 patients with lung cysts.
Four of these 10 cases were also negative in ELISA
during the same period of follow-up, the other 6
ELISA-positive cases showed a progressive decrease
of antibody levels during the follow-up period. In
contrast to these CCE lung cases, NCCE patients,
independent of the organ localization, showed a
persistent recognition of AgB subcomponents that
was still signiﬁcantly high even 5 years post-treat-
ment (Fig. 1B). At the time of diagnosis (day 0), high
65 kDa
55 kDa
21 kDa
16 kDa
12 kDa
8 kDa
65 kDa
55 kDa
21 kDa
16 kDa
12 kDa
8 kDa
CC N1N2 N3 N D01M 6M1Y 2Y 3Y D0 D7 1M 6M 1Y D0 D71M6M1Y5Y D0 1M 6M 1Y 5Y
D0 D71M 6M1Y 2Y 3Y4Y D0 D71M 6M 1Y 2Y D0 D71M 6M1Y 2Y 3Y 4Y D01M 6M 1Y 2Y3Y 4Y5Y
(A)
(B)
Fig. 2. Immunoblotting follow up, exempliﬁed with sera from 4 out of 40 CCE (A) and 4 out of 14 NCCE patients (B)
under non-reducing conditions. D0: serum samples collected before surgery, D7: one week after surgery, 1M: one
month after, 6M: six months after, 1Y: 1 year post surgery, 2Y: 2 years, and so on. Four negative control sera (N1–N4)
as well as a conjugate control (CC) are included in (A).
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antibody concentrations were generally detected by
ELISA in patients with liver cysts and in multiple
cyst localizations including the lungs. Throughout
subsequent follow-up, the progressive decrease of
antibodies was more rapid for lung and liver locali-
zation than for multiple locations. Thus, sero-
negativity was reached at the end time-point of
follow up in only 1 out of 11multiple cyst localization
(9%)versus 7 out of 18 (39%) lung cysts and4out of 11
(36.4%) liver cysts.
Statistically signiﬁcant diﬀerences were observed
between the two groups (CCE and NCCE) at day 0
(before surgery: P=0.04) and starting from 6
months until 5 years follow up (6M/P=0.010),
(12M/P=10x4), (24M, 36M, 48M/P=10x3), (60M/
P=0.02). Furthermore, CCE patients who were
cured by surgery showed a progressive disappear-
ance of the diﬀerent antigen bands starting from 6
months post-surgery, as exempliﬁed in Figs 2 and 3.
Interestingly, in some cases, there was an earlier
disappearance of the 16 kDa AgB subcomponent,
while the 8 kDa disappeared later.
No signiﬁcant eﬀect on the antibody binding
activity in immunoblotting was observed when
37 kDa
21 kDa
16 kDa
12 kDa
8 kDa
37 kDa
21 kDa
16 kDa
12 kDa
8 kDa
CC N1 N2 N3 N4 D0 1M 6M 1Y 3Y D0 D7 6M 1Y 3Y D0 1M 6M 2Y 5Y
D0 1M 6M 2Y 4Y D0 D7 6M 1Y 3Y D0 1M 6M 3Y 5Y
(A)
(B)
Fig. 3. Immunoblotting follow up, exempliﬁed with sera from 3 out of 40 CCE (A) and 3 out of 14 NCCE patients (B)
under reducing conditions. D0: serum samples collected before surgery, D7: one week after surgery, 1M: one month
after, 6M: six months after, 1Y: 1 year post surgery, 2Y: 2 years and so on. Four negative control sera (N1–N4) as well
as a conjugate control (CC) are included in (A).
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comparing surgery/ABZ-treatment versus surgery
alone (data not shown), irrespective of the CCE
or NCCE status. Nevertheless, CCE patients ex-
hibited a slightly higher rate of seronegativity by
immunoblotting than by ELISA, but the discrimi-
nating power was also no better when comparing the
combined surgery/ABZ-treatment with surgery
alone (4 immunoblot negatives out of 6 patients
treated with surgery/ABZ versus 26 out of 34
patients only treated by surgery, respectively). The 2
NCCE patients who were only medically treated
with ABZ exhibited no decrease in the banding
pattern and no decrease in the band-staining inten-
sity.
DISCUSSION
Hydatidosis is a cosmopolitan disease and is highly
endemic in most of the Mediterranean countries.
One of the characteristics of hydatid disease is the
relatively frequent occurrence of relapses after sur-
gery. Such relapses may be due to several reasons,
predominantly as follows: (i) cyst (or cysts) has
(have) been incompletely removed by surgery, or the
cyst has ruptured, and spilling of hydatid ﬂuid con-
taining protoscolices occurred, causing secondary
infection; (ii) cyst (or all the cysts) has (have) been
completely removed as reported by the surgeon, but
additional small, initially undetectable cysts were
growing months or years after initial therapy; (iii)
patients cured by surgery may putatively become
reinfected months or years after successful therapy.
However, such an event may be relatively unlikely,
and is also controversially discussed, as protective
immunity may prevent reinfection in former cured
CE patients, but such protective immunity has not
yet been really proven. Nevertheless, the relatively
high frequency of relapses requires follow-up
methods that are suitable for monitoring the rad-
icality of surgical cyst resection or the viablity status
of putatively remaining cyst material, including
protoscolices. Follow-up sera from cured (CCE) and
non-cured (NCCE) young hydatidosis patients
treated by surgery were subjected to ELISA and
immunoblot testing; both methods were based upon
crude sheep hydatid ﬂuid as a source of parasite
antigen. Serological reactivities of CCE patients in
ELISA increased during an initial 6-month period
after surgery, followed later by a progressive de-
crease. In NCCE patients, a similar increase was
observed for the ﬁrst 6-month period, but the sub-
sequent decrease was less pronounced. This diﬀer-
ence between CCE and NCCE patients was not
marked enough to allow a statistically signiﬁcant
diﬀerentiation between the two groups. These
ELISA results are consistent with those found in
other studies such as those published by Gottstein
et al. (1986) ; Craig et al. (1986) ; Bulut et al. (2001)
and Force et al. (1992). In contrast, Zarzoza et al.
(1999) reported a higher rate of sera becoming sero-
negative in their study (25.9% and 16.6% of cured
patients at 4 and 5 years post-surgery, respectively).
However, this eﬀect may be attributable to the fact
that only cases of pulmonary cyst localization were
investigated. It has been shown that lung cysts yield
lower serological responses than hepatic ones (Babba
et al. 1994; Force et al. 1992). Immunoblotting data
demonstrated that there was a decrease in antibody
reactivities with regard to the 8 and 16 kDa AgB
subunits, as seen as a 50% recognition rate at 6
months and a 14.3% recognition rate at 4 years post-
surgery. None of the sera reacted with these bands at
5 years post-surgery. All non-cured cases (100%)
showed a strong persistence in reactivities with these
bands during the follow up. Thus, our results are
similar to those of Doiz et al. (2001), in which
reactivities with AgB fractions (12, 16, 20 kDa) dis-
appeared within 11 months of treatment, whereas
non-cured patients remained seropositive for a
3-year period post-surgery in 50%, 75% and 75% for
the 12, 16 and 20 kDa bands, respectively. AgB
exhibits an improved diagnostic value respective
to infection risk factors (Hernandez et al. 2005).
Therefore, the assessment of puriﬁed antigens such
as the synthetic AgB peptide published by Gonzales-
Sapienza et al. (2000) for the follow-up of CE
patients may be of interest.
In our study, 10 CE patients presented both
negative ELISA and immunoblot ﬁndings for the
whole study period. Seronegativity in cases of lung
cyst localization had for long been recognized as a
diagnostic problem (Lightowlers and Gottstein,
1995), and this problem also holds true for post-
treatment follow-up studies. The generally accepted
explanation for this phenomenon is a marked separ-
ation of the cysts from the surrounding pulmonal
tissue and a consequent weak release of parasite
metabolites (antigens) into the pulmonal circulation,
resulting in a greatly diminished antigen stimulation
and host immune response at the immunologically
competent sites in the lungs. The consequence is that
such cases should be monitored by imaging tech-
niques rather than by serology. With regard to ABZ-
therapy, ELISA and immunoblotting yielded no
signiﬁcant diﬀerences between sera from CCE or
NCCE patients who underwent combined surgery
and ABZ-therapy or those who were operated and
received no therapy.
In conclusion, ELISA and immunoblotting
have demonstrated their relative usefulness in the
post-therapeutic serological follow-up of patients
presenting diﬀerent courses of disease, i.e. cure or
non-cure as monitored by the occurrence of relapses
or persitence of symptoms during a 4–5 year period
after initiation of treatment. Immunoblotting ap-
pears to be the test that best reﬂects the evolution of
disease after curative surgery, since it becomes
negative with regard to AgB banding reactivity,
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the eﬀect starting from 6 months post-surgery.
However, the lack of sensitivity of immunoblotting
in certain cases of lung cyst localization limits
its employment in these cases. Physical imaging
examinations are also very useful in predicting cyst
evolution, since it has been shown to be more sensi-
tive than serology (Babba et al. 1994). This reinforces
the necessity to combine both serology and imaging
procedures for optimal monitoring of cystic echin-
coccosis/hydatidosis.
In the light of our ﬁndings, we suggest that im-
munoblotting should be carried-out to follow-up
operated hydatidosis patients at least 6 months and
12 months post-operatively, respectively, and sub-
sequently once a year for a minimum period of 4
years, using the interpretation criteria as outlined
above.
Finally, the search for new approaches to improve
respective serological tools is still needed. Using
other sources of antigens such as protoscoleces or
recombinant proteins may be an option to develop
serological means with an improved prediction of the
disease activity. Furthermore, we anticipate a more
detailed analysis of non-cured patients, whowill have
to be grouped according to diﬀerent means of re-
lapses (as outlined above). The search for parameters
that could discriminate between such subgroups of
NCCE patients may provide additional useful in-
formation for clinicians to facilitate decisive selection
of further treatment strategies to be implemented for
such patients.
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